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Abstract
Background: The risk of developing lung cancer is high in patients with intersti-
tial lung disease (ILD), as few treatment options are available. Immune check-
point inhibitors (ICI) are used for the treatment of non-small cell lung cancer
(NSCLC) in clinical practice; however, in patients with preexisting ILD, the risk
of ICI-related pneumonitis is unknown. We evaluated the efﬁcacy and lung tox-
icity of nivolumab in patients with NSCLC and ILD.
Methods: We retrospectively reviewed the medical records of 216 NSCLC
patients who had received nivolumab therapy. The existence of ILD in these
patients was determined by lung computed tomography ﬁndings; 26 patients had
ILD. We evaluated the efﬁcacy of nivolumab by measuring the response rate
(RR), progression-free survival (PFS) duration, and lung toxicity by incidence,
severity, and outcome of nivolumab-related ILD.
Results: The RR and median PFS of the ILD and non-ILD groups were 27% ver-
sus 13% (P = 0.078) and 2.7 (95% conﬁdence interval [CI], 1.7–5.3) versus
2.9 months (95% CI 2.1–3.4; P = 0.919), respectively. The incidences of total and
severe nivolumab-related pneumonitis were signiﬁcantly higher in the ILD group
than in the non-ILD group (31% vs. 12%, P = 0.014 and 19% vs. 5%, P = 0.022,
respectively). No death from nivolumab-related pneumonitis occurred. Over 50%
of the patients in both groups with nivolumab-related pneumonitis showed
improvement over time.
Conclusion: Relative to the non-ILD group, nivolumab-related pneumonitis was
observed more frequently in the ILD group; however, most cases were manageable.
Introduction
Patients with interstitial lung disease (ILD) have a two-
fold higher risk of developing lung cancer than smokers
without ILD or chronic obstructive pulmonary disease
(COPD).1,2 Lung cancer patients with ILD have few
treatment options because surgery, radiotherapy, and
chemotherapy elevate the risk of exacerbation of
ILD.3–10
Treatment-related pneumonitis is relatively common in
Japanese patients with lung cancer.8,11 In Japan, during
treatment for advanced or recurrent lung cancer, the inci-
dence of pneumonitis induced by cytotoxic chemotherapies
and molecular targeted agents are reported to be 2–6% and
3.5–4.5%, respectively.7,8,11–13 The mortality rate of
chemotherapy-related pneumonitis is reported as approxi-
mately 30% and is believed to be the most common cause
of treatment-related death.14 Moreover, incidence and mor-
tality rates of treatment-related pneumonitis are higher in
patients with preexisting ILD.7,8,15
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In recent years, immune checkpoint inhibitors (ICIs)
have been used for the treatment of non-small cell lung
cancer (NSCLC) in clinical practice.16–19 The incidence of
ICI-related pneumonitis, including some fatal cases, is
reported as 1–12%.16–22 In contrast to cytotoxic chemother-
apy or molecular-targeted agent-related pneumonitis, most
ICI-related pneumonitis patients appear to be sensitive to
treatment with corticosteroids; however, the risk of ICI-
related pneumonitis in patients with preexisting ILD is
unknown.20
Thus, we evaluated the efﬁcacy and lung toxicity of
nivolumab in patients with NSCLC and preexisting ILD.
Methods
Patients
We retrospectively reviewed the electronic medical records
of NSCLC patients who were treated with nivolumab at
three institutions (the National Hospital Organization
Kyoto Medical Center, Kyoto University Hospital, and the
Japanese Red Cross Fukui Hospital) between 24 December
2015 and 31 December 2016. The study was initiated after
approval from the Institutional Review Board of each insti-
tution and complied with the principles of the Declaration
of Helsinki.
All of the patients were diagnosed with advanced or
recurrent NSCLC after surgical resection or radiotherapy
and were refractory to one or more chemotherapeutic regi-
mens. The patients were administered at least one dose of
nivolumab intravenously (3 mg/kg every two weeks or lon-
ger). The observation period was between 24 December
2015 and 30 June 2017. We identiﬁed patients with preex-
isting ILD (ILD group) by reviewing chest computed
tomography (CT) images taken just before the initiation of
ﬁrst-line chemotherapy. Patients with a history of drug-
induced pneumonitis or those with radiation-related
ﬁbrotic lesions alone in the lung were excluded from the
ILD group. We obtained clinical data of participating
patients from the electronic medical records of each insti-
tution, including: age, gender, smoking history, Eastern
Cooperative Oncology Group Performance Status (ECOG-
PS), histology, any existing driver gene mutations, prior
therapies (including surgery and radiotherapy), and the
comorbidity of autoimmune diseases.
Evaluation of preexisting interstitial lung
disease (ILD)
We deﬁned the ILD group of patients as those who exhib-
ited at least one of the following CT ﬁndings in no less
than two lobes of the lung: ground glass appearance,
reticular opacity, consolidation (excluding infectious
pneumonia), traction bronchiectasis, centrilobular nodular-
ity, and honeycombing.20 As previously reported, the
extent of preexisting ILD was measured using a ﬁve-point
scale for the upper, middle, and lower zones of the lung
(0, none; 1 < 5%; 2, 5–25%; 3, 25–50%; and 4 > 50%).23
Radiological patterns of preexisting ILD were classiﬁed
following the American Thoracic Society (ATS)/European
Respiratory Society (ERS) International Multidisciplinary
Classiﬁcation of Interstitial Pneumonia: usual interstitial
pneumonia (UIP), nonspeciﬁc interstitial pneumonia
(NSIP), cryptogenic organizing pneumonia (COP), and
acute interstitial pneumonia (AIP).24 The existence, extent,
and radiographic patterns of ILD were assessed by two pul-
monologists not directly involved in the treatment of
patients and observed by a specialist in idiopathic intersti-
tial pneumonia and another board certiﬁed radiologist.
Interobserver disagreements were resolved by consensus.
Evaluation of efﬁcacy
The effect of nivolumab treatment was evaluated by mea-
suring the response rate (RR), disease control rate (DCR),
and progression-free survival (PFS) in patients. The RR
and DCR were assessed using Response Evaluation Criteria
in Solid Tumors version 1.1.25 We deﬁned PFS as the dura-
tion between the initiation of nivolumab treatment and the
date of conﬁrmation of disease progression or death from
any cause. We compared the RR, DCR, and PFS values
between the ILD and non-ILD groups.
Evaluation of toxicity
Nivolumab-related pneumonitis was deﬁned as the appear-
ance of speciﬁc ILD-related CT ﬁndings (as described in
the previous section), and was observed between the date
of initial administration and one month after the last
administration of nivolumab.20 The following data were
also reviewed in cases with newly developed nivolumab-
related pneumonitis: time until onset, toxicity grade,
radiographic pattern, treatment, and outcome of
nivolumab-related pneumonitis. The toxicity grade of
pneumonitis was evaluated according to the National Can-
cer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0.26 Radiographic
patterns were classiﬁed into UIP, NSIP, COP, and AIP pat-
tern groups following the ATS/ERS International Multidis-
ciplinary Classiﬁcation of Interstitial Pneumonia.24 Based
on the association between the radiographic pattern of pre-
existing ILD and nivolumab-related pneumonitis, the ILD
patients were categorized into two types: (i) exacerbation
type in which both radiographic patterns of ILD were
similar; and (ii) de novo type in which radiographic
patterns of nivolumab-related pneumonitis differed from
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that of preexisting ILD. We compared the incidence, sever-
ity, time to onset, immunosuppressant treatment, and out-
come of nivolumab-related pneumonitis in patients with
and without preexisting ILD who developed nivolumab-
related pneumonitis. We also compared the potential risk
factors of pneumonitis (smoking, ECOG-PS, and the radio-
graphic pattern of preexisting ILD) between patients with
and without nivolumab-related pneumonitis in all patients
and in the ILD group.8,27
Statistics
Continuous data are presented as the mean and range, and
comparisons were made using Student’s t or Mann–
Whitney U tests. Categorical data were obtained as counts
and percentages, and Fisher’s exact tests were used to com-
pare variables. The PFS curves were generated by the
Kaplan–Meier method and compared using log-rank tests.
A P value < 0.05 was considered statistically signiﬁcant,
with 95% conﬁdence intervals (CIs). All statistical analyses
were performed using R version 3.4.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Baseline characteristics
We reviewed the medical records of 216 NSCLC patients
who had received treatment with nivolumab. None of the
patients experienced drug-induced pneumonitis, one patient
was observed with radiation-related ﬁbrotic changes in the
lung caused by treatment for esophageal cancer, and one
patient developed COP after pulmonary resection but had
been cured before the initial chemotherapy; these patients
were classiﬁed in the non-ILD group.
The patients were classiﬁed into ILD (26 patients, 12%)
and non-ILD (190 patients) groups. The baseline characteris-
tics of all patients are summarized in Table 1. The median
age was 69 years and the majority of patients were men
(71%) and current or former smokers (79%). Fifty-six
patients (9 in the ILD, 47 in the non-ILD group) had an
ECOG-PS score of ≥ 2. Eleven patients were comorbid with
autoimmune diseases and all cases were rheumatoid arthritis
(RA). There were signiﬁcant differences between the groups
regarding the number of patients carrying a positive EGFR
mutation (0% vs. 22%; P = 0.003), with RA (27% vs. 2%;
P < 0.001), or who had undergone prior thoracic radiother-
apy (11% vs. 32%; P = 0.039). The median number of regi-
mens received before nivolumab was administered was 1 in
the ILD and 2 in the non-ILD group (P = 0.001).
Radiographic characteristics
of preexisting ILD
The most common radiographic pattern of preexisting ILD,
the NSIP pattern, was noted in 14 patients, followed by the
UIP pattern in 12 patients. Other patterns were not observed
in these patients. Based on the extent (or severity) and
Table 1 Baseline characteristics
N
Total ILD group Non-ILD group
216 26 190 P
Age 69 (30–89) 71 (55–85) 69 (30–89) 0.243
Gender (Male) 154 (71) 20 (77) 134 (71) 0.645
Current of former smoker 170 (79) 25 (96) 145 (76) 0.02
ECOG-PS 0, 1 160 (74) 17 (65) 143 (75) 0.339
ECOG-PS ≥ 2 56 (26) 9 (35) 47 (25) 0.339
Histology Adenocarcinoma 135 (62) 13 (50) 122 (64) 0.424
Squamous 57 (27) 11 (42) 46 (24)
Other 23 (1) 2 (8) 21 (2)
Positive EGFR mutation 42 (19) 0 (0) 42 (22) 0.003
Positive ALK translocation 6 (3) 0 (0) 6 (3) > 0.99
Comorbidity with RA 11 (5) 7 (27) 4 (2) < 0.001
Prior curable operation 40 (19) 1 (4) 39 (21) 0.055
Thoracic radiotherapy 63 (29) 3 (11) 60 (32) 0.039
No. of previous regimens 2 (1–15) 1 (1–8) 2 (1–15) < 0.001
Line of chemotherapy Second 82 (38) 18 (69) 64 (34) 0.001
Third or later 134 (62) 8 (31) 126 (66)
Radiographic pattern NSIP 14 (54)
of preexisting ILD UIP 12 (46)
Data are shown as median (range) or number (%). Radiographic patterns of interstitial lung disease (ILD) were categorized according to the American
Thoracic Society/European Respiratory Society International Multidisciplinary Classiﬁcation of Interstitial Pneumonia. ECOG-PS, Eastern Cooperative
Oncology Group-performance status; NSIP, non-speciﬁc interstitial pneumonia; RA, rheumatoid arthritis; UIP, usual interstitial pneumonia.
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location of preexisting ILD, each patient was scored on a scale
ranging from 0 to 4 and grouped in three lung zones (Fig 1).
For the upper, middle, and lower zones, the median preexist-
ing ILD extension scores were 1 (< 5%), 1 (< 5%), and
2 (5–25%), respectively. All patients in the ILD group had a
high ILD extent score in the lower zone of the lung. Of the
26 patients, 20 (77%) had a score of ≤ 2 (5–25%) and 4 (15%)
had a score of ≤ 1 (< 5%) in one of the zones. None of the
patients achieved a score of 4 (< 50%) for any zone.
Efﬁcacy of nivolumab
A median number of ﬁve doses of nivolumab were admin-
istered to the ILD (range 1—37) and non-ILD (range
1–33) groups (P = 0.564) (Table 2). Following nivolumab
treatment, the RR of the ILD group was 27% versus 13%
for the non-ILD group (P = 0.078). The DCR was 58%
versus 44% in the ILD and non-ILD groups (P = 0.214),
respectively. The median PFS rates of the ILD and non-
ILD groups were 2.7 (95% CI 1.7–5.3) and 2.9 (95% CI
2.1–3.4) months (P = 0.919), respectively (Fig 2). There
were no signiﬁcant differences in the RR, DCR, and PFS
ﬁndings between the two groups.
Incidence, characteristics, treatment,
and outcomes of nivolumab-related
pneumonitis
Of the 26 patients with preexisting ILD, eight patients
developed nivolumab-related pneumonitis. Four patients
were categorized with the exacerbation type and the
remaining four exhibited the de novo type (Table 3). The
CT images in Figure 3 present examples of the exacerba-
tion (Case 7) and de novo (Case 6) types of nivolumab-
related pneumonitis. The incidence of nivolumab-related
pneumonitis was signiﬁcantly higher in the ILD than in
the non-ILD group (31% vs. 12%; P = 0.014) (Table 4).
The frequency of severe nivolumab-related pneumonitis
(equivalent to grade ≥ 3, evaluated according to CTCAE

















Figure 1 A bar graph indicating the number of patients with their
extent scores for preexisting interstitial lung disease (ILD) in the upper,
middle, and lower zones. None of the patients achieved a score of
4 (> 50%) in any zone, a score of 3 (25–50%) in the middle zone, or a
score of 0 (none) in the lower zone. The proportion of patients with a
score of 0 or 1 decreased in the order of the upper, middle, and lower
zones.










5 (1–37) 5 (1–37) 5 (1–33) 0.564
Best
response
CR 7 (3) 1 (4) 6 (3) 0.205
PR 25 (12) 6 (23) 19 (10)
SD 67 (31) 8 (31) 59 (31)
PD 117 (54) 11 (42) 106 (56)
Disease
control rate
99 (46) 15 (58) 84 (44) 0.214
Response rate 32 (15) 7 (27) 25 (13) 0.078
Data are shown as median (range) or number (%). The best response
was evaluated according to Response Evaluation Criteria in Solid
Tumors version 1.1. CR, complete response; ILD, interstitial lung dis-
ease; PD, progressive disease; PR, partial response; SD, stable disease.
N Median OS P value
Non-ILD group 190 2.9 (2.1-3.4) 0.919
ILD group 26 2.7 (1.7-5.3)


















Figure 2 The progression-free survival (PFS) curve was generated
according to the Kaplan–Meier method. The median PFS of the patients
with preexisting interstitial lung disease (ILD group) was comparable to
that of patients without preexisting ILD (non-ILD group). The P value
was estimated using the log-rank test.
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ILD group (19% vs. 5%; P = 0.022). No pneumonitis-
related death was observed in this study. There were no
signiﬁcant differences in the median duration and number
of doses of nivolumab until the onset of nivolumab-related
pneumonitis between the groups. COP was the major
radiographic pattern of nivolumab-related pneumonitis in
both groups. Immunosuppressants, including systemic cor-
ticosteroids for the treatment of nivolumab-related pneu-
monitis, were initiated for 5 (63%) patients in the ILD and
16 (73%) in the non-ILD group (P = 0.666). Only one
patient in the non-ILD group was treated with cyclospor-
ine A and inﬂiximab for nivolumab-related pneumonitis,
while the others were treated with systemic corticosteroids
alone or without any immunosuppressant. An improve-
ment in symptoms was achieved in over half of the
patients who developed nivolumab-related pneumonitis,
regardless of comorbidity with ILD. In all patients, the
incidence of nivolumab-related pneumonitis was signiﬁ-
cantly higher in men (Table 5). Patients with RA appeared
to develop nivolumab-related pneumonitis more fre-
quently, but this result was not signiﬁcant (P = 0.05). In
the ILD group, the incidence of nivolumab-related pneu-
monitis was not signiﬁcantly inﬂuenced by risk factors of
drug-induced pneumonitis, such as age, gender, smoking
history, ECOG-PS, C-reactive protein, and radiographic
patterns of preexisting ILD (Table 5).
Discussion
In this study, we ﬁrst evaluated the efﬁcacy and incidence
of nivolumab-related pneumonitis in patients with NSCLC
and preexisting ILD, and later compared them with
patients without preexisting ILD under real-world condi-
tions. Our ﬁndings demonstrate that the RR, DCR, and
PFS values associated with nivolumab therapy in patients
with preexisting ILD were comparable to those without
preexisting ILD. Although the incidences of nivolumab-
related pneumonitis and severe nivolumab-related
pneumonitis were signiﬁcantly higher in patients with pre-
existing ILD, the treatment outcome of nivolumab-related
pneumonitis was comparable for patients with and without
preexisting ILD. No death resulting from nivolumab-
related pneumonitis was observed.
The RR of nivolumab in the ILD group was higher than
in the non-ILD group but was not statistically signiﬁcant.
PFS in response to nivolumab was similar in both groups.
The efﬁcacy of nivolumab in the ILD group was remark-
able. This observation contradicts the ﬁndings of a previ-
ous report demonstrating that the PFS of patients with
preexisting ILD undergoing cytotoxic chemotherapies is
signiﬁcantly lower relative to those without preexisting
ILD.10 Our result might be inﬂuenced by the signiﬁcantly
improved RR of 30% in patients who developed
nivolumab-related pneumonitis versus 12% in those who
did not (P = 0.023). However, this ﬁnding may be biased
because of the low proportion of patients with a poor
ECOG-PS score, which is reported to be associated with
the efﬁcacy of nivolumab treatment (17% in patients who
developed pneumonitis vs. 27% in those who did not).28
Another pilot trial reported similar favorable efﬁcacy of
nivolumab in patients with NSCLC and ILD, and demon-
strated a high RR of 50%.29 One reason for the efﬁcacy of
nivolumab in the ILD group may be the high proportion
of patients without EGFR mutations or with a smoking
history (as evidenced in patients with NSCLC and ILD),27
which appeared to be associated with a better treatment
outcome in patients treated with ICIs.28,30 Another expla-
nation may be the tumor mutation burden, as a high
tumor mutation burden is associated with a better
response to nivolumab.31 Patients with idiopathic pulmo-
nary ﬁbrosis are known to exhibit DNA microsatellite
instability, and this may account for the high mutation
burden in these patients.32 For these reasons, we believe
that treatment with nivolumab may exert favorable effects
on the clinical outcomes of patients with NSCLC
and ILD.
Table 3 Characteristics of nivolumab-related pneumonitis in patients with preexisting ILD
Case Age Histology ECOG-PS
Radiographic pattern of
Category Severity OutcomePreexisting ILD Pneumonitis
1 72 Squamous 2 UIP AIP Exacerbation 3 Improved
2 76 Adenocarcinoma 1 NSIP AIP Exacerbation 4 Improved
3 72 Adenocarcinoma 0 NSIP COP De novo 1 Improved
4 69 Squamous 1 UIP COP De novo 3 Improved
5 62 Squamous 1 UIP AIP Exacerbation 3 Progressed
6 74 Adenocarcinoma 0 NSIP COP De novo 3 Improved
7 55 Adenocarcinoma 1 NSIP NSIP Exacerbation 1 No change
8 65 Squamous 0 NSIP COP De novo 1 Improved
All patients were male and current or former smokers. The severity of interstitial lung disease (ILD) was evaluated according to the National Cancer
Institute Common Terminology Criteria for Adverse Events version 4.0. AIP, acute interstitial pneumonia; COP, cryptogenic organizing pneumonia;
NSIP, non-speciﬁc interstitial pneumonia; UIP, usual interstitial pneumonia.
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Although the incidences of total and severe nivolumab-
related pneumonitis were signiﬁcantly higher in the ILD
than in the non-ILD group, the treatment outcome of
nivolumab-related pneumonitis was similar in both groups.
Moreover, most patients who developed nivolumab-related
pneumonitis were sensitive to systemic corticosteroid ther-
apy; only one patient from the non-ILD group required
cyclosporine A and inﬂiximab treatment, but the patient
later had a concurrent diagnosis of pneumonitis and tumor
invasion.33 The benign outcome of nivolumab-related
pneumonitis in the ILD group was possibly a result of one
of the following reasons. First, the majority of patients in
the ILD group had a low preexisting ILD extent score;
therefore more than two-thirds of the patients in the ILD
group could be treated with nivolumab as second-line che-
motherapy. Second, nivolumab-related pneumonitis
resulted in low mortality and was more responsive to
immunosuppressive agents than the pneumonitis induced
by cytotoxic chemotherapies or molecular-targeted
agents.8,15,20,21 Finally, frequent chest radiographic examina-
tion of preexisting ILD might have led to the early detec-
tion of nivolumab-related ILD, but may also have partially
contributed to the higher incidence of nivolumab-related
pneumonitis in the ILD group. The low mortality and
benign course of nivolumab-related pneumonitis suggests
that treatment with nivolumab may be tolerable in patients
with NSCLC and those exhibiting mild symptoms of
preexisting ILD.
In the total cohort, the incidence of nivolumab-related
ILD was signiﬁcantly higher in men and patients with pre-
existing ILD. These factors are reported to be potential risk
factors of pneumonitis in patients treated with cytotoxic
chemotherapies.8,27 In the ILD group, we could not deter-
mine the risk factor responsible for the incidence and
a b
c d
Figure 3 The computed tomography (CT) images of the patient’s lung were acquired (a,b) before the initial administration of nivolumab and (c,d)
at the onset of nivolumab-related ILD. (a,c) An example of the exacerbation type (Case 7 in Table 3), in which new ground glass opacities and con-
solidation are distributed along the site of preexisting ILD. (b,d) An example of the de novo type (Case 6 in Table 3), in which ground glass appear-
ance and consolidation are distributed around lung metastases that are not involved with the preexisting ILD.
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severity of nivolumab-related pneumonitis. We hypothesize
that there are two etiologies of nivolumab-related pneumo-
nitis in the ILD group: (i) the exacerbation type, showing
exacerbation of a preexisting ILD condition; and (ii) the de
novo type, newly induced by nivolumab and independent
of preexisting ILD. Moreover, based on the observation
that patients with nivolumab-related pneumonitis who pre-
sent a typical radiographic pattern, speciﬁcally an AIP pat-
tern, are reported to follow a poorer course of recovery
than those with an atypical pattern, we hypothesized that
there was an association between the severity and radio-
graphic pattern (or category) of nivolumab-related pneu-
monitis;20,34,35 however, we did not ﬁnd any association.
We acknowledge four major limitations of this study.
First, this study was retrospective, and some of the baseline
characteristics were signiﬁcantly different between the ILD
and non-ILD groups. Our cohort consisted of patients who
were excluded from clinical trials: patients with a poor
Table 4 Occurrence and treatment course of nivolumab-induced pneumonitis
ILD group
Factors Total All patterns UIP pattern NSIP pattern Non-ILD group P
n 216 26 12 14 190
ILD 30 (14) 8 (31) 3 (25) 5 (36) 22 (12) 0.014
ILD grade 1, 2 15 (50) 3 (38) 0 (0) 3 (60) 12 (55) 0.022
3, 4 15 (50) 5 (62) 3 (25) 2 (14) 10 (45)
Time to onset (months) 2.3 (0.07–13.1) 2.3 (0.7–4.4) 0.9 (0.7–2.3) 2.7 (1.1–4.4) 2.3 (0.07–13.1) 0.433
Dose of nivolumab until the
onset of ILD
5.5 (1–28) 4 (1–10) 2 (1–5) 7 (3–10) 6 (1–28) 0.384
Radiographic pattern of AIP 5 (17) 3 (37) 2 (67) 1 (20) 2 (9)
pneumonitis COP 18 (60) 4 (50) 1 (33) 3 (60) 14 (64) 0.277
NSIP 7 (23) 1 (13) 0 (0) 1 (20) 6 (27)
UIP 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Requirement of immunosuppressant 21 (70) 5 (63) 3 (100) 2 (40) 16 (73) 0.666
Outcome 19 (63) 6 (74) 2 (67) 4 (80) 13 (59) 0.851
6 (20) 1 (13) 0 (0) 1 (20) 5 (23)
5 (17) 1 (13) 1 (33) 0 (0) 4 (18)
Data are shown as median (range) or number (%). The toxicity grade was evaluated according to National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.0. A comparison between interstitial lung disease (ILD) and non-ILD groups was performed using Fisher’s exact
or Mann–Whitney U tests where appropriate. AIP, acute interstitial pneumonia; COP, cryptogenic organizing pneumonia; NSIP, non-speciﬁc intersti-
tial pneumonia; UIP, usual interstitial pneumonia.
Table 5 Risk factors of nivolumab-related pneumonitis in all the patients or ILD group
N
Total ILD group
Pneumonitis − Pneumonitis + Pneumonitis − Pneumonitis +
186 30 P 18 8 P
Age ≥ 75 38 (20) 4 (13) 0.461 5 (28) 1 (13) 0.628
Gender (male) 127 (68) 27 (90) 0.016 12 (67) 8 (100) 0.132
Current or former smoker 143 (77) 27 (90) 0.148 17 (94) 8 (100) > 0.99
ECOG-PS ≥ 2 51 (27) 5 (17) 0.265 8 (44) 1 (13) 0.19
Positive EGFR mutation 38 (20) 4 (13) 0.461 0 (0) 0 (0) > 0.99
Comorbidity with RA 7 (4) 4 (13) 0.05 4 (22) 3 (38) 0.635
Thoracic radiotherapy 54 (29) 9 (30) >0.99 2 (11) 1 (13) > 0.99
Line of chemotherapy Second 69 (37) 13 (43) 0.547 13 (72) 5 (63) 0.667
Third or later 117 (63) 17 (57) 5 (28) 3 (38)
CRP > 50 mg/l 29 (16) 3 (10) 0.583 4 (22) 0 (0) 0.277
Total dose of nivolumab 5.0 (1–30) 6.0 (1–37) 0.653 5.5 (1–30) 5.0 (1–37) 0.978
With preexisting ILD 18 (10) 8 (27) 0.014
Radiographic pattern of NSIP 9 (50) 5 (63) 0.683
preexisting ILD UIP 9 (50) 3 (38)
P values were calculated by using Fisher’s exact or Mann-Whitney U tests where appropriate. CRP, C-reactive protein; ECOG-PS, Eastern Cooperative
Oncology Group-performance status; ILD, interstitial lung disease; NSIP, non-speciﬁc interstitial pneumonia; RA, rheumatoid arthritis; UIP, usual inter-
stitial pneumonia.
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ECOG-PS score, preexisting ILD, autoimmune diseases, or
no measurable lesion. Second, our patient sample was
insufﬁcient to determine factors associated with the devel-
opment of nivolumab-related pneumonitis. Third, diagno-
ses of preexisting ILD and nivolumab-related pneumonitis
were largely dependent on CT ﬁndings; thus histological
and physiological diagnoses of ILD are lacking. It is
believed that CT scans may present an overestimation of
the comorbidity rate of ILD. The ILD comorbidity rate in
our study was 12%, which is comparable to the previously
reported incidence of radiographic interstitial abnormality
in patients with NSCLC.9 Considering the higher incidence
of comorbidity with ILD in the Japanese population, the
incidence of preexisting ILD was reasonable in this
study.7,8,11 Finally, this cohort only consisted of Japanese
patients. As Japanese people may be susceptible to drug-
induced pneumonitis, the results of this study may vary
among different ethnic groups.8,11 Despite these limitations,
this multicenter study elucidated the efﬁcacy and lung tox-
icity of nivolumab treatment in patients with preexisting
ILD under real-world conditions.
The results of our study suggest that the incidence of
total and severe nivolumab-related pneumonitis were
higher in NSCLC patients with ILD than in those without
ILD. However, nivolumab-related pneumonitis was man-
ageable in patients exhibiting a mild form of preexisting
ILD. Considering the comparable efﬁcacy of nivolumab
therapy in patients with NSCLC and preexisting ILD, nivo-
lumab therapy might become a promising treatment
option for patients with these conditions; however, careful
monitoring for early detection of pneumonitis is required.
Additional prospective studies are needed to determine the
efﬁcacy and safety of nivolumab treatment in patients with
NSCLC and preexisting ILD.
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